Amgen GmbH

Biotechnology

Products/services: Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses.

    • Short facts
      • Manufacturer
    • Year founded 1989
    • 315 Employees (site)
    • Turnover: 50m <125m EUR
    Company
    Amgen GmbH
    Street
    Riesdstr.24
    PC/City
    80902 München
    County
    Munich, Federal State Capital / Upper Bavaria
    Phone
    +49 89 149096-0
    Fax
    +49 89 149096-2000
    Email
    not available
    Homepage
    http://www.amgen.de
    Language skills
    English, German
    Location Map
    Key to Bavaria Map
  • Core competencies

    Amgen's corporate mission is to be the world leader in developing and delivering important, cost-effective therapeutics based on cellular and molecular biology. The company's first product, EPOGEN® (Epoetin alfa), stimulates and regulates the production of red blood cells. Amgen's second product, NEUPOGEN® (Filgrastim), is a recombinant granulocyte colony-stimulating factor (G-CSF) that selectively stimulates growth of infection-fighting white blood cells known as neutrophils. In 2001 Amgen launched a new drug, called Aranesp®, which also stimulates the production of red blood cells. Aranesp® was created by rational drug design and has a threefold longer halflife time compared to Epogen®. In 2002 AMGEN launched a second generation G-CSF called Neulasta® which also stimulates the growth of neutrophils. Neulasta® has an important advantage. Due to its pegylation Neulasta® has a longer half-life time and therefore has to be administered only once per chemotherapy cycle whereas Neupogen® has to be administered daily.

    Key sectors / sub-sectors
    • Biotechnology: Molecular diagnostics for humans
    • Biotechnology: Therapeutic drug development
    NACE industries
    • Wholesale of chemical products 46.75
    Certification

    not available

    Sales markets - target industries
    not available
    Sales markets - target countries
    not available
    Cooperation offers
    not available